Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

ELTS Score (CML)

The ELTS score predicts the risk of dying from CML-related causes in patients treated with Tyrosine Kinase Inhibitors (TKIs).

Evidence-based context for fast calculator use

Purpose:
ELTS Score estimates long-term CML-specific survival risk in chronic myeloid leukemia patients on TKI therapy to guide treatment intensity.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age, Spleen Size, Peripheral Blood Blasts, Platelet Count
Reference:
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56.
HomeELTS Score (CML)
Pin your most used calculators here by clicking the star in the dropdown.

ELTS Score (CML)

years
cm
%
x10⁹/L

Clinical Context & Background

The ELTS score predicts the risk of dying from CML-related causes in patients treated with Tyrosine Kinase Inhibitors (TKIs). It discriminates leukemia-specific survival better than the Sokal score in the modern TKI era.
Primary Source EvidencePfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56.
Formula Logic
0.0025*(Age/10)^3 + 0.0615*Spleen + 0.1052*Blasts + 0.4104*(Plt/1000)^-0.5

Reference Data

Risk GroupScoreProbability of Dying of CML
Low≤ 1.5680Low
Intermediate1.5680 - 2.2185Intermediate
High> 2.2185High

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use ELTS Score (CML) when eLTS Score estimates long-term CML-specific survival risk in chronic myeloid leukemia patients on TKI therapy to guide treatment intensity.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age, Spleen Size, Peripheral Blood Blasts, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should ELTS Score (CML) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can ELTS Score (CML) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.